GALNT9

Across TCGA pan-cancer cohorts, GALNT9 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GALNT9 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GALNT9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNT9 expression acts as an unfavorable survival marker.

BLCA, DLBC, and BRCA are the cancer types where GALNT9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.114	0.626	<.001	24	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
BRCA	OS	Median	All	0.761	0.963	.041	9	view →
COAD	DFS	Median	IV	0.035	0.501	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GALNT9–BLCA (DFS)

Open the BLCA breakdown →